Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M187Revenue (TTM) $M0.6Net Margin (%)-5,518.3Altman Z-Score4.0
Enterprise Value $M142EPS (TTM) $-0.7Operating Margin %-5,612.9Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-5,518.3Higher ROA y-yN
Price/Book4.010-y EBITDA Growth Rate %1.1Quick Ratio9.4Cash flow > EarningsY
Price/Sales1,8255-y EBITDA Growth Rate %7.5Current Ratio9.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-48.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-54.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M51.1ROIC % (ttm)-273.8Gross Margin Increase y-yN

Gurus Latest Trades with CGEN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

CGEN is held by these investors:



CGEN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about CGEN:

    News about CGEN:

    Articles On GuruFocus.com
    Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Mon Aug 07 2017 
    Compugen Welcomes Paul Sekhri as its New Chairman of the Board Aug 02 2017 
    Compugen Reports Second Quarter 2017 Results Aug 02 2017 
    Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology Jul 26 2017 
    Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate Jul 25 2017 
    Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET Jul 24 2017 
    Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Jun 05 2017 
    Compugen Provides Update on COM701 and Upcoming Presentations May 31 2017 
    Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors May 25 2017 
    Compugen to Present at Two Upcoming Investor Conferences in June May 23 2017 

    More From Other Websites
    Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next... Aug 07 2017
    Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen Aug 04 2017
    Compugen reports 2Q loss Aug 02 2017
    Compugen Welcomes Paul Sekhri as its New Chairman of the Board Aug 02 2017
    Compugen Reports Second Quarter 2017 Results Aug 02 2017
    Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology Jul 26 2017
    Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate Jul 25 2017
    Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET Jul 24 2017
    Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical... Jun 05 2017
    Compugen Provides Update on COM701 and Upcoming Presentations May 31 2017
    Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors May 25 2017
    Compugen to Present at Two Upcoming Investor Conferences in June May 23 2017
    Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session May 22 2017
    Investor Network: Compugen Ltd. to Host Earnings Call May 09 2017
    Compugen Reports First Quarter 2017 Results May 09 2017
    Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO May 04 2017
    Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET Apr 26 2017
    ETFs with exposure to Compugen Ltd. : April 25, 2017 Apr 25 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}